StockData

CVRx vs Kestra Medical Technologies

CVRX and KMTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CVRX and KMTS compare

Kestra Medical Technologies is the larger company, worth 102 times as much as CVRx ($1.7B against $16.3M).

Kestra Medical Technologies grew revenue faster over the last twelve months (60.7% versus 12.0% for CVRx).

CVRx keeps more of each dollar of sales as profit, with a net margin of −84.9% compared with −140% at Kestra Medical Technologies.

CVRx scores higher on the StockData Score (8 against 5 for Kestra Medical Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCVRXKMTS
Size and price
Market cap$16.3M$1.7B
Share price$0.613$27.97
Change, 1 year−93.1%12.3%
Change, 5 years−95.3%–
Beta (5Y)−0.961.26
Employees223443
StockData Score
Total score8 (better)5
Valuation score3 (better)0
Growth score33
Performance score1 (better)0
Health score12 (better)
Dividend score00
Valuation
P/S0.3× (better)15.6×
P/B0.8×–
FCF yield−251%−7.4% (better)
Fair value$7.09–
Margin of safety91.4%–
Growth
Revenue growth (TTM)12.0%60.7% (better)
Revenue growth, 5Y average56.4%–
Profitability
Gross margin86.9% (better)53.9%
Operating margin−79.5% (better)−134%
Net margin−84.9% (better)−140%
FCF margin−67.1% (better)−115%
Return on equity−133%–
Return on invested capital−293%–
Financial health
Debt / equity2.94–
Interest coverage−8.1× (better)−19.0×
Current ratio8.04 (better)4.69
Altman Z-score−9.294.75 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield−2.9%–
Shareholder yield−2.9%0.00% (better)
Ownership
Held by institutions57.4%98.6%
Held by insiders49.9%44.0%
Insider net buying, 12 months$247K (better)−$15.3M
Short interest, % of float13.6%12.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.